Indication
Uncontrolled Moderate to Severe
1 clinical trial
1 product
Product
OmalizumabClinical trial
A Phase III, Randomized, Multicenter, Double-blind, Two-armed, Parallel, Active-controlled, Equivalency Clinical Trial to Compare Efficacy and Safety of Omalizumab (CinnaGen, Iran) in Comparison to Xolair® (Genentech, Inc., USA And Novartis Pharmaceuticals Corp, Switzerland) in Patients With Uncontrolled Moderate to Severe Allergic AsthmaStatus: Completed, Estimated PCD: 2023-01-15